Status:
NOT_YET_RECRUITING
Novel Biomarkers Related Xuebijing Injection Improves Sepsis
Lead Sponsor:
Southeast University, China
Conditions:
Sepsis
Eligibility:
All Genders
18-75 years
Brief Summary
Sepsis is a life-threatening clinical syndrome of organ dysfunction caused by dysregulation of the body's response to infection, and is a common cause of ICU admission for critically ill patients, pos...
Eligibility Criteria
Inclusion
- Meeting the Sepsis 3.0 diagnostic criteria;
- SOFA score ≥ 2 and \< 13;
- Signed informed consent.
Exclusion
- Age \<18 years or \>75 years;
- Pregnant or lactating women;
- Presence of severe primary diseases including malignant tumors severe hematologic disorders and HIV infection;
- Current use of immunosuppressants or history of organ transplantation within the past 6 months;
- Comorbidities that significantly affect vascular endothelial structure and function such as acute myocardial infarction.
Key Trial Info
Start Date :
March 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06920420
Start Date
March 30 2025
End Date
December 31 2028
Last Update
April 9 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.